Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04475-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Koki Murakami und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AMED (Japan Agency for Medical Research and Development), JSPS KAKENHI Grant, Kobayashi Foundation for Cancer Research.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is among the most malignant primary brain tumors, necessitating the development of novel therapies. Intracranial injection of chimeric antigen receptor (CAR)-T cell therapy is effective against GBM. However, whether intracranially injected CAR-T cells persist in the brain for long periods is unclear. In this study, we established a syngeneic murine model of GBM by injecting GL261 murine GBM cells expressing human B7-H3. After confirming tumor engraftment, murine T cells transduced with CAR-targeting human B7-H3 were injected intratumorally. Reduced tumor burden and enhanced survival were observed in mice injected with B7-H3 CAR-T cells compared with those injected with control T cells. CAR-T cells were distinctly detected in the brain 1 week after CAR-T cell injection, but disappeared 2 weeks after injection. In the syngeneic mouse model, intracranially injected CAR-T cells have the potential to eradicate GBM but do not persist in the brain for long, suggesting that intracranial injections of CAR-T cells need to be repeatedly administered, as has been done in several clinical trials. It will be important to develop strategies to enhance persistence of CAR-T cells in the brain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.
- Department of Neurosurgery, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan. n-kijima@nsurg.med.osaka-u.ac.jp.
- World Premier International Immunology Frontier Research Center, The University of Osaka, Suita, Osaka, Japan.
- World Premier International Immunology Frontier Research Center, The University of Osaka, Suita, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.
- Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan. hnaoki@bldon.med.osaka-u.ac.jp.
Förderung
- AMED (Japan Agency for Medical Research and Development)
- JSPS KAKENHI Grant
- Kobayashi Foundation for Cancer Research
- Japan Brain Foundation
- Osaka Community Foundation
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Yasuda Kinen Medical Foundation
- Uehara Memorial Foundation
Zitieren
APA
Murakami, K., Kijima, N., Kuroda, H., Tachi, T., Ikeda, S., Nakagawa, K., Wada, Y., Hagioka, T., Hatanaka, N., Hirayama, R., Kishima, H., & Hosen, N. (2026). Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04475-z
Vancouver
Murakami K, Kijima N, Kuroda H, Tachi T, Ikeda S, Nakagawa K, et al. Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04475-z
BibTeX
@article{Murakami2026,
author = {Murakami, Koki and Kijima, Noriyuki and Kuroda, Hideki and Tachi, Tetsuro and Ikeda, Shunya and Nakagawa, Kanji and Wada, Yuki and Hagioka, Tatsuya and Hatanaka, Naoko and Hirayama, Ryuichi and Kishima, Haruhiko and Hosen, Naoki},
title = {Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04475-z}
}
EUVIMED